Haleon Recalls Robitussin Honey CF Max Day and Nighttime Syrups Due to Contamination

Voluntary Recall Details

Haleon, a health and wellness product manufacturer, has issued a voluntary recall for eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult. The recall is initiated due to potential microbial contamination, raising concerns about severe or life-threatening adverse events, especially in immunocompromised individuals.

Robitussin Honey CF Max Day Adult

• Affected Lots: T10810
• Expiry Date: October 31, 2025

Robitussin Honey CF Max Day Adult

• Affected Lots: T08730, T08731, T08732, T08733, T10808
• Expiry Dates: May 31, 2025 (T08730, T08731, T08732, T08733), September 30, 2025 (T10808)

Robitussin Honey CF Max Nighttime Adult

• Affected Lots: T08740, T08742
• Expiry Date: June 30, 2026

Potential Risks and Health Concerns

The microbial contamination in the affected products poses risks, particularly for immunocompromised individuals. Potential adverse events include severe or life-threatening conditions such as fungemia or disseminated fungal infection. While the likelihood of life-threatening infections is lower in non-immunocompromised consumers, the occurrence of infections requiring medical intervention cannot be completely ruled out.

Consumer Instructions

Consumers who have purchased the recalled products are urged to stop consumption immediately. If you have any of the affected lots, contact Haleon’s Consumer Relations team at +1-800-245-1040 (Monday through Friday, 8 AM to 6 PM Eastern Time) or via email at [email protected]. The company is providing instructions for the return of all recalled products.

No Adverse Events Reported

As of now, Haleon has not received any reports of adverse events related to this recall. However, the voluntary recall is conducted to ensure consumer safety and address potential health risks associated with the use of the contaminated products.

Reporting Adverse Events

Consumers experiencing adverse reactions or quality problems related to the use of these products are encouraged to report them to the FDA’s MedWatch Adverse Event Reporting program. Reports can be submitted online at www.fda.gov/medwatch/report.htm or through regular mail or fax using the downloadable form at www.fda.gov/MedWatch/getforms.htm.

FDA’s Oversight

This recall is being conducted with the knowledge and cooperation of the U.S. Food and Drug Administration (FDA). The FDA relies on voluntary reporting of adverse events to monitor and address safety concerns associated with medical products, including drugs.

Conclusion

As cold and flu season continues, it is crucial for consumers to be aware of product recalls to ensure their safety. If you possess any of the recalled Robitussin products, promptly discontinue use and follow the provided instructions for product return. It’s essential to remain vigilant about product recalls to protect your health and well-being.